This comprehensive analysis delves into Pfizer’s current position, future prospects, and the factors shaping its stock outlook. Financial Performance and 2025 Guidance ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

Both TEGSEDI and WAYLIVRA are legacy assets that were originally brought to the EU market via an Ionis subsidiary, Akcea ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $135.18, with a high estimate of $155.00 and a low estimate of $110.00. Highlighting a 3.58% ...

Pfizer (NYSE:PFE) recently announced positive topline results from its Phase 3 BASIS study for HYMPAVZI™ and declared a third ...

This article conducts technical analysis and provides forecasts for top trending stocks like Plug Power (PLUG), Uber, and ...

Pfizer ( ($PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Pfizer Inc. is actively advancing its ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is initiating a Phase 1 clinical study titled A PHASE 1, ...

Get the latest Pfizer Inc. (PFE) stock news and headlines to help you in your trading and investing decisions.

AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the ...

Pfizer has earned a consensus rating of “Moderate Buy” from fifteen analysts, with only one calling it a “sell.” The average ...